Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W CODEINE.
Head-to-head clinical analysis: SEMPREX D versus TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W CODEINE.
SEMPREX-D vs TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, producing analgesia and antitussive effects. Triprolidine is a first-generation antihistamine blocking H1 receptors, reducing histamine effects. Pseudoephedrine is a sympathomimetic amine acting as a decongestant via alpha-adrenergic receptor agonism in respiratory tract mucosa.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
Oral: 1 tablet (triprolidine 2.5 mg, pseudoephedrine 60 mg, codeine 30 mg) every 4-6 hours as needed; maximum 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Codeine: 2.5-3.5 hours; clinical context: short half-life necessitates frequent dosing. Triprolidine: 3-5 hours; clinical context: typical dosing every 4-6 hours. Pseudoephedrine: 5-8 hours (alkaline urine prolongs to ~10-13 hours); clinical context: extended-release formulations available.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Codeine: renal elimination of metabolites (primarily codeine-6-glucuronide, norcodeine, and morphine glucuronides); approximately 90% excreted renally, with about 10% as unchanged codeine. Triprolidine: renal elimination (80-90% as metabolites, <5% unchanged). Pseudoephedrine: renal elimination (70-90% unchanged, dependent on urine pH).
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine